This message was sent to ##Email##
|
|
|
|
|
| |
By Jason Poquette
 Community pharmacy is stressful, even on our best days. There is the pressure to fill more prescriptions, check for drug interactions and answer questions at an increasingly faster pace. But maybe nothing — except possibly dealing with a prescription error — is more stressful than getting a surprise inspection from your state board of pharmacy. I have been managing pharmacies for enough years to have experienced plenty of such inspections, and I'm happy to share some advice.
READ MORE
2017 Fall Conference
Sept. 16 — Phoenix, Arizona
Details and Registration Coming Soon!
Masquerade Ball 2017
Sept. 30 — Chandler, Arizona
You can register by clicking here!
ASHP
At Baxter Regional Medical Center, a flurry of activity followed FDA’s April 20 announcement of new warnings and contraindications in the labeling for codeine- and tramadol-containing products to prevent respiratory depression and other adverse events in infants and children.
READ MORE
APhA
Use of NSAIDs, including naproxen, was associated with an increased risk of acute myocardial infarction, with the onset of risk occurring during the first week of therapy and a more pronounced risk occurring at higher doses, according to results of a systematic review and meta-analysis of real-world individual patient data published online in BMJ.
READ MORE
Pharmacy Practice News
Providers are familiar with drug administration safety measures—such as ensuring the right drug is administered to the right patient at the right time—but many are likely unaware of the scrupulous examination of drug packaging, labeling and naming that drugs undergo before receiving FDA approval.
READ MORE
Pharmacy Times
Lupin Pharmaceuticals Inc. has issued a nationwide recall of one lot of its oral contraceptive tablets Mibelas 24 Fe (norethindrone acetate and ethinyl estradiol chewable tablets and ferrous fumarate) because of out-of-sequence tablet packaging and missing expiration and lot information.
READ MORE
ModernMedicine
Pharmacist interventions in clinical trials of two major diabetes drugs resulted in more reliable outcomes for the trials, according to a recent study.
The first study of its kind examining the impact of pharmacists on the outcomes of clinical trial was published in the April 2017 issue of Clinical Therapeutics.
READ MORE
|
Missed last week's issue? See which articles your colleagues read most.
|
|
Don't be left behind. Click here to see what else you missed.
|
Pharmacy Practice News
The FDA requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated extended-release oxymorphone hydrochloride, from the market.
READ MORE
Medical News Today
Researchers have long known that diabetes can increase a woman's risk of breast cancer. A new study, however, suggests that this risk could be significantly reduced with long-term use of low-dose aspirin.
READ MORE
The Wall Street Journal
The nation’s worsening opioid crisis has become another sticking point in Republican plans to dismantle major portions of the Affordable Care Act, with key GOP senators hesitating to support a bill that could threaten addiction treatment for millions of people.
READ MORE
|
|
|
|
50 Minthorn Blvd.Suite 800, Thornhill, Ontario L3T 7X8
|
